Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alprostadil topical - Seelos Therapeutics

Next Previous
Drug Profile

Alprostadil topical - Seelos Therapeutics

Alternative Names: Alprox-TD; Befar; Cold Chain Vitaros; Femprox; RayVa; Room Temperature Vitaros; Topical ED treatment - Seelos Therapeutics; Virirec; Vitaros; Vytaros; WC-3036

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NexMed
  • Developer Apricus Biosciences; Ferring Pharmaceuticals; Laboratoires Majorelle; Recordati; Seelos Therapeutics
  • Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Erectile dysfunction
  • Phase II Raynaud's disease
  • Suspended Female sexual dysfunction
  • No development reported Premature ejaculation; Wounds

Most Recent Events

  • 16 Feb 2021 Simple Pharma acquires Alprostadil topical from Ferring Pharmaceuticals
  • 25 Aug 2020 Launched for Erectile dysfunction in Greece (Topical)
  • 08 May 2020 Allergan has been acquired and merged into AbbVie

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top